Episode 71

The Science of APOE4: Why Evolution Kept the Alzheimer's Gene

38:31 September 8, 2026 By Dr. Ravi Kumar MD
Apple Podcasts Spotify Amazon Music Pocket Casts YouTube

Show Notes

If a gene were truly bad for us, evolution would have deleted it. So why is APOE4, the single strongest common genetic risk factor for Alzheimer’s disease, still sitting in about one in four human beings on the planet?

That is the question Dr. Ravi Kumar takes apart in this solo episode, and he has a personal stake in it. He carries one copy of APOE4 himself. He has been going deep into the literature for a paper he is writing, and the more he read, the more the standard grim message about this gene stopped making sense to him, both evolutionarily and as plain common sense.

He starts with the biology, because APOE gets talked about constantly and almost never explained. APOE stands for apolipoprotein E, and its job is moving fat around: triglycerides, cholesterol, phospholipids. Fats cannot float freely in blood, so they need a protein to ferry them. In the brain this matters enormously, because lipoproteins from your blood cannot cross the blood brain barrier. Your brain runs its own fat economy, and APOE is the main truck doing all the hauling. That is not a small job in an organ that is roughly 60% lipid by dry weight, where every cell membrane, every myelin sheath, and every synapse you rebuild when you learn something new is built out of fat that has to arrive in the right place at the right time.

The difference between the variants comes down to a single amino acid. E3 has a cysteine at one position; E4 has an arginine. That one swap makes the protein fold in on itself and latch onto its own back, like the difference between a person standing with their arms loose at their sides and a person with their arms folded tightly across their chest. Same person, very different posture, and that posture changes what the molecule can do: looser grip on the liver’s LDL receptors, more competition for those receptors after a fatty meal, a less stable molecule overall, and less efficient clearance of amyloid out of the brain.

Then come the numbers, and this is where Ravi slows down, because this is exactly where unnecessary fear gets manufactured. The famous figure is a 14.9 odds ratio from a 1997 JAMA meta-analysis, and it gets repeated everywhere as though two copies makes you 15 times more likely to develop Alzheimer’s. That is not what an odds ratio tells you about your personal risk. The number that maps onto your actual life is lifetime risk, and by age 85 that runs roughly 51% for men with two copies and 60% for women, against a general population baseline of about 11% and 14%. Which means even with two copies of the highest risk version of this gene, roughly four in ten men and four in ten women reach 85 without ever developing Alzheimer’s disease.

The evolutionary answer is the heart of the episode. APOE4 is not the mutant, it is the original. Sequencing work comparing the human APOE gene to the chimpanzee version finds the chimp gene most closely resembles human APOE4, with E3 and E2 as the newer arrivals, and E3 steadily gaining ground over roughly the past 200,000 years. To see what E4 was good for, you have to look at people still living closer to the ancestral condition. In the Tsimane, a forager horticulturalist population in the Bolivian Amazon, a 2017 study of 372 people found that carriers without much parasite exposure recalled about 16% fewer words, the same direction we see in industrialized populations, but among those carrying a heavy parasite burden the pattern flipped entirely: APOE4 carriers held their cognition while non-carriers declined. A 2021 study of over 1,200 Tsimane adults found carriers ran roughly 30% lower C reactive protein, a quieter baseline immune system that swings hard the moment a real threat appears. Less a thermostat stuck on high, more a very sensitive smoke detector.

The strongest piece of the puzzle has nothing to do with cognition at all. A 2023 study of 795 Tsimane women found that one APOE4 allele tracked with 0.3 to 0.5 more children and two alleles with 1.4 to 2.1 more, with first births about 0.8 years earlier and shorter gaps between them. A partial replication in over 4,000 women in rural Ghana found roughly one additional child per allele in the high pathogen group and nothing at all in the low exposure group. Natural selection does not care whether you are sharp at 75. It is a numbers game scored on descendants, and a gene that buys you extra surviving children spreads fast even if the bill arrives 50 years later.

So what changed? Three things. Time, because far more of us now live into the window where Alzheimer’s prevalence goes vertical, and among the Hadza only about 8 of every 100 births reached 80, which left selection almost no leverage on late-life harm. Our immune environment, because the sensitive detector that once had real fires to find now sits in bodies carrying visceral fat, insulin resistance, disrupted sleep, and chronic stress, and it never stops running. And our food, with ultra-processed products now supplying nearly 58% of the average American’s daily calories and almost 90% of added sugar, driving the metabolic syndrome that a pooled analysis of over 2,000,000 people links to roughly 60% higher dementia risk in type 2 diabetes.

The last third of the episode is the practical part: the levers. Deep sleep and the glymphatic system, where a single night of deprivation raised amyloid about 5% in the thalamus and hippocampus of 20 healthy adults. Insulin sensitivity, where diabetes on top of APOE4 carried a 5.5-fold relative risk increase over having neither. Midlife blood pressure and cholesterol in your 40s and 50s. Structured movement, resistance training, a Mediterranean style pattern, and real social engagement. Then the modifiable risk factors from the 2024 Lancet Commission, including the one piece of this that rests on a randomized trial rather than an association: the ACHIEVE trial, where hearing aids cut the rate of cognitive decline roughly in half in older adults already at higher risk.

Ravi’s closing reframe is the point of the whole episode. A defect is something you have and cannot do anything about. A mismatch is something you can understand and then modify your environment to fit. APOE4 is a risk factor, not a verdict.

Episode Resources

In this episode, you will discover:

  • APOE4 is the ancestral version, not the mutation: Comparing human DNA to chimpanzee DNA shows the chimp version lines up closest with APOE4, which means E3 and E2 are the newer variants and E4 is the original form our lineage carried
  • One amino acid changes everything: E3 carries a cysteine where E4 carries an arginine, and that single swap folds the protein in on itself, weakening its grip on liver LDL receptors and its ability to haul amyloid out of the brain
  • Your brain runs its own fat economy: Blood lipoproteins cannot cross the blood brain barrier, so an organ that is roughly 60% lipid by dry weight has to manage its own cholesterol and lipid transport, and APOE is the delivery truck
  • APOE sits at the crossroads of fat and immunity: It is made mainly by astrocytes and microglia, the brain’s resident immune cells, which is the detail that makes the rest of the evolutionary story click
  • An odds ratio is not a lifetime risk: The widely quoted 14.9 from a 1997 JAMA meta-analysis does not mean two copies makes you 15 times more likely to get Alzheimer’s, and reading it that way creates fear that the data does not support
  • The real lifetime numbers: By age 85, roughly 51% for men with two copies and 60% for women, about 23% and 30% with one copy, against a general population baseline near 11% and 14%
  • Four in ten reach 85 untouched: Even with two copies of the highest risk variant, roughly four in ten men and four in ten women reach 85 without ever developing Alzheimer’s disease
  • Pathology is not the same as dementia: Nearly everyone with two copies develops the amyloid plaques and tau tangles you can see on a scan or under a microscope, yet about half still reach 85 with a clear, strong mind
  • The parasite flip in the Tsimane: In a 2017 study of 372 people, carriers with little parasite exposure recalled about 16% fewer words, but among those with heavy parasite burden the pattern reversed and carriers held their cognition while non-carriers declined
  • A smoke detector, not a stuck thermostat: Tsimane APOE4 carriers ran roughly 30% lower baseline C reactive protein but mounted a harder immune response once a real threat appeared, which is exactly the profile you want in a world full of infection
  • The fertility advantage: A 2023 study of 795 Tsimane women found one allele tracked with 0.3 to 0.5 more children and two alleles with 1.4 to 2.1 more, with first births about 0.8 years earlier, and a Ghana study of over 4,000 women replicated the effect only in the high pathogen group
  • Selection had almost no leverage at 80: Among the Hadza, only about 8 of every 100 births reached 80, so harm arriving that late was nearly invisible to natural selection while the fertility and infection benefits acted on everyone
  • Ultra-processed food is a brand new variable in this story: It now supplies nearly 58% of the average American’s daily calories and almost 90% of added sugar, and a pooled analysis of over 2,000,000 people ties type 2 diabetes to roughly 60% higher dementia risk
  • One lost night raises amyloid: A 2018 study kept 20 healthy adults awake for a single night and found amyloid rose about 5% in the thalamus and hippocampus, the regions the glymphatic system clears while you sleep
  • Diabetes plus APOE4 multiplies risk: A 2002 study found the combination carried a 5.5-fold relative risk increase compared with having neither, one of the clearest gene-environment interactions in the literature
  • Midlife is the window that counts: A 2001 BMJ study of nearly 1,500 people found high blood pressure in your 40s and 50s roughly doubled later Alzheimer’s risk, high midlife cholesterol did the same, and both together more than tripled it
  • Hearing aids are the one randomized win: The ACHIEVE trial in The Lancet in 2023 found hearing aids cut the rate of cognitive decline by roughly half among older adults already at higher baseline risk, which is a controlled trial rather than an association
  • The rest of the modifiable list, with real numbers: Uncorrected hearing loss around 37% higher risk, social isolation 55% to 60%, uncorrected vision loss about 38%, current smoking about 30%, depression roughly double, heavy midlife drinking around 20%, and air pollution on a sliding dose scale

Key Takeaways

APOE4 is not a design flaw, it is a mismatch. It was tuned for a world of infection, scarcity, and early reproduction, and it now runs inside bodies living in a world of abundance, sterility, and 80 year lifespans. The gene did not change. The environment did.

That distinction is the whole point. A defect is something you have and cannot act on. A mismatch is something you can understand, and then change the environment around it. That is why this reframe is practical rather than merely interesting.

Learn to read the statistic that applies to you. Odds ratios are a statistical tool for comparing groups, not a multiplier on your personal fate. Lifetime risk is the number that answers the question you are actually asking, and it is far less frightening than the figure that circulates online.

Pathology and dementia are two different things. Nearly every person with two copies accumulates amyloid and tau. About half of them still reach 85 with their mind intact. Something is protecting those people, and a good part of it is modifiable.

The evolutionary bargain came due late, on purpose. The benefits of APOE4, infection defense and fertility, paid out early in life when they could influence how many descendants you left behind. The cost arrived at an age almost nobody used to reach, which is exactly why selection never removed it.

Sleep is not a nice-to-have if you carry APOE4. Amyloid clearance runs through the glymphatic system during deep, slow wave sleep, and this is the protein APOE4 already clears less efficiently. Treat sleep like the most powerful medication available to you.

Metabolic health is the highest-yield lever you control. Insulin sensitivity, blood pressure in midlife, weight, and muscle mass all feed into the same pathway. Diabetes on top of APOE4 is one of the sharpest risk multipliers in the entire literature.

Fix the boring things: hearing, vision, isolation, mood. These are unglamorous, correctable, and carry surprisingly large risk numbers. Hearing aids in particular are backed by a randomized trial, which almost nothing else on this list can claim.

A risk factor is not a verdict. Ravi is an APOE4/E3 heterozygote and says plainly that he is not scared of dementia. The most powerful tools we have are still sleep, movement, food, and metabolic health, and every one of them is fully modifiable by you.

Transcript

[00:00 –> 00:38] Dr. Ravi Kumar: Let me ask you something. If a gene were truly bad for us, how long do you think it would take for evolution to just get rid of it? Well, probably not long on an evolutionary time scale, because disadvantageous traits are ruthlessly cut and discarded by natural selection. And the reason why I’m asking you this question is because there’s a gene sitting in about one in four human beings on this planet right now That is the single strongest common genetic risk factor for Alzheimer’s that we know of. And if you carry one copy of it, your risk of developing Alzheimer’s disease roughly doubles.

[00:38 –> 00:53] Dr. Ravi Kumar: If you carry two copies, it climbs closer to fivefold. And that gene is not a recent mutation. It’s not some modern accident. It’s the original version that we evolved with. So it’s the oldest form of the gene in the human lineage.

[00:54 –> 01:18] Dr. Ravi Kumar: And every single one of our distant ancestors likely carried it. Natural selection had hundreds of thousands of years to delete it, and it didn’t. So either evolution made a catastrophic mistake, or we’re just looking at this genetic trait all wrong. The gene I’m talking about is APOE, and specifically the APOE4 variant.

[01:19 –> 01:43] Dr. Ravi Kumar: My name is Dr. Ravi Kumar. I’m a neurosurgeon in search of the causes of human illness and the solutions that help us heal and thrive. I want you to join me on a journey of discovery as I turn over every stone in search of the roots of disease and the mysteries of our resilience. The human body is a mysterious and miraculous machine with an amazing ability to self heal.

[01:43 –> 01:51] Dr. Ravi Kumar: Let us question everything and discover our true potentials. Welcome to The Dr Kumar Discovery.

[01:54 –> 02:14] Dr. Ravi Kumar: Welcome back to The Dr Kumar Discovery. My name’s Dr. Ravi Kumar. Today, we’re doing a deep dive on a topic that’s very relevant to all of us. We’re talking about neurodegenerative diseases like Alzheimer’s that take us, or people we love, away from the world during what should be the golden years of our life.

[02:14 –> 02:51] Dr. Ravi Kumar: It’s a scary, often helpless feeling disease, and we’ve been told that the gene variant APOE4 is a major culprit for it, and that it’s practically written into our destiny. I myself carry one copy of APOE4, and honestly, the prevailing message about it just hasn’t made sense to me. Not from an evolutionary standpoint, and not from a common sense one either. So I’ve been going deep into the literature for a paper that I’m writing, and the more I read, the more I realize that this is a story that I need to tell out loud, start to finish, and then share it with everyone. And that’s why I’m doing this episode.

[02:51 –> 03:44] Dr. Ravi Kumar: So if you’ve had a genetic test done, maybe through 23andMe, or maybe your doctor ran a test, there’s a reasonable chance that you already know your APOE status. And if you found out that you carry an APOE4 allele, there’s a reasonable chance that someone handed you that result with a grim look on their face and not a lot else. I’ve seen that happen, and it’s a terrible way to receive information about your own body. So for anyone out there wondering about their Alzheimer’s risk, or wondering how to interpret their APOE status, or the APOE status of someone they love, this episode is exactly for you. By the end, you’re gonna understand what APOE actually does in the brain, why the APOE version, or variant, almost certainly helped our ancestors survive, and how the modern world became mismatched with the benefits of this gene variant.

[03:44 –> 04:19] Dr. Ravi Kumar: And even though there are some scary numbers around this gene, you’ll realize that most people with this gene, even people with two copies, the highest risk people, do not develop Alzheimer’s every time. It’s not a straight line from gene to disease like we’ve often heard. It’s much more complicated, and complicated is very good news, because that means there are levers you can pull, and by the end of this episode, you’ll know what those levers are and how to pull them. One more thing before we dive in, it’s just a quick disclaimer. I’m a doctor, but I’m not your doctor.

[04:19 –> 04:48] Dr. Ravi Kumar: This show is for informational purposes only. Everything in this episode is meant to empower you, so take this knowledge, ask better questions, and work with your doctor to build a more informed, healthier life. And just to be clear, this show is also separate from my role as Assistant Professor at UNC. Also, real quick, before we get started, I just want to talk to you about the show, because the show is growing really fast, and right now, The Dr Kumar Discovery reaches over 100,000 people every month.

[04:48 –> 05:21] Dr. Ravi Kumar: But a lot of the listeners aren’t subscribed, so if you’re enjoying this show, please hit subscribe and leave a review wherever you’re listening. It dramatically helps the show reach more people, and reaching more people with good, honest, unbiased information is the whole point of what I’m doing. Alright, let’s get into it. Let’s start with what this gene even is in the first place, because APOE is one of those things that gets talked about constantly and almost never explained. APOE stands for apolipoprotein E.

[05:21 –> 05:53] Dr. Ravi Kumar: Its main job is moving fatty molecules around, like triglycerides, cholesterol, and phospholipids. You see, fats just can’t float freely in blood or water, so they need to be ferried around by proteins like APOE. APOE is found all over your body, but specifically in the brain, it’s the main lipoprotein, kind of like LDL is in the body. And this is an important concept because your brain runs its own fat economy. That’s what I like to call it an economy because they’re dealing in the currency of fat and energy.

[05:53 –> 06:32] Dr. Ravi Kumar: Lipoproteins from your blood can’t cross the blood brain barrier, so the brain has to handle its own cholesterol and lipid transport internally. And APOE is the main truck doing all the hauling of those lipids. That matters enormously because your brain is a fatty organ, roughly 60% lipid by dry weight. So if you dried out your brain, 60% of the weight of it is lipids. And every cell membrane, every myelin sheath, every synapse that you rebuild, every time you learn something new, is built out of fat that has to get delivered to the right place at the right time.

[06:32 –> 06:55] Dr. Ravi Kumar: And APOE is that delivery truck. So most of your brain APOE is made by astrocytes. These are star shaped supportive cells that do a huge amount of housekeeping in the brain, and also made by microglia, which are the brain’s resident immune cells. So already, you can see something interesting here. APOE sits at the intersection of fat transport and immune function.

[06:56 –> 07:25] Dr. Ravi Kumar: Stick that fact in your back pocket, because it’ll play into the story a little later. Now, there are three common versions of the APOE gene in humans, E2, E3, and E4. The difference is extremely small. There’s like one position where one amino acid can change, and the protein becomes a whole new variant. For example, E3, which is by far the most common version, has an amino acid called cysteine at that spot, and APOE4 has an arginine in that spot instead.

[07:25 –> 07:47] Dr. Ravi Kumar: One swap, and it changes the whole shape of the molecule. The APOE protein has these two ends connected by flexible hinges, kinda like arms. In E3, those ends are fully mobile and functional. In APOE4, that arginine swings a neighboring piece of the protein across and latches onto the back of the molecule. The whole thing folds in and basically grabs itself.

[07:48 –> 08:24] Dr. Ravi Kumar: A good analogy is like a person standing with their arms loose at their sides, versus a person who’s got their arms folded tightly across their chest. It’s the same person, but a very different posture, and that posture changes what the molecule can do. So let’s actually walk through the mechanism of how APOE4 variants actually change your physiology. Okay, so first, people with APOE4 variants tend to have higher LDL cholesterol. And the reason is, is that VLDL particles, which are the large fluffy particles that eventually become LDL particles, have APOE4 in it.

[08:24 –> 09:13] Dr. Ravi Kumar: And because of that, they don’t grip the liver’s LDL receptors as well as VLDL particles that have APOE3 in it, if that’s your genetic variant. So it attaches more loosely and lets go faster, so these particles, which eventually become LDL molecules, accumulate in the bloodstream. Second, after a meal, APOE4’s other job, which is hauling big triglyceride rich particles, actually gets more aggressive, and those particles compete for the exact same liver receptors that LDL needs to get cleared out of the bloodstream and into the liver. So picture a parking garage with a fixed number of spots. The triglyceride rich particles get to pull in and take those first spots, and that leaves LDL circling the block longer before it can get pulled out of your bloodstream.

[09:14 –> 09:43] Dr. Ravi Kumar: That’s very likely why APOE4 carriers tend to run higher baseline LDL levels, especially after fatty meals. APOE4 is also a less stable molecule generally. It’s more prone to breaking into fragments, and in the brain, it’s less efficient at delivering lipids to neurons that need them for repair. And it’s also less efficient at hauling amyloid, which is a sticky protein that clumps together in the brains of people with Alzheimer’s. It’s less efficient at hauling that amyloid out.

[09:43 –> 10:34] Dr. Ravi Kumar: So people with APOE4 variants tend to accumulate amyloid, which then triggers a second protein inside neurons called tau to get chemically tagged in a way that makes it fall off of the neuron’s internal scaffolding, which is the structure that the cell uses like train tracks to move nutrients around. So that process is called tau hyperphosphorylation, and the tangled, collapsed tau molecules form neurofibrillary tangles, and that actually chokes off the neuron and kills it. So amyloid plaques and tau tangles together are what we mean when we talk about Alzheimer’s pathology. That’s where you take a look at the raw tissue of the brain in someone who has Alzheimer’s, and this is what you see under the microscope. So it’s essentially the physical evidence of the disease process that’s visible on a scan or under a microscope.

[10:35 –> 11:16] Dr. Ravi Kumar: But, and this is a big but, these findings are not the same thing as having dementia. Keep that distinction in mind because it’ll make sense in a few minutes. Okay, so now you understand what APOE4 is, and how it works, and why it causes these problems. But now let’s talk about numbers, and let’s do it very carefully because this is exactly where a lot of the unnecessary fear gets created. A pooled analysis in the Journal of Alzheimer’s Disease in 2021, drawing on 121 studies in roughly 389,000 people across 38 countries, found that about 24% of people carry at least one APOE4 allele, and about 2% carry two.

[11:16 –> 12:08] Dr. Ravi Kumar: That varies by ancestry, so it’s roughly 19% to 37%, depending on the population. So a single global number is often misleading, but we can say this with certainty, roughly a quarter of humanity carries at least one copy of APOE4. When talking about risk, there was a classic meta analysis in JAMA back in 1997 that gave odds ratios of roughly 3.2 for one copy of APOE4 and 14.9 for two, compared to people who inherited the common E3 version from both parents. Now that 14.9 odds ratio figure sounds pretty scary, and it gets repeated everywhere as though it means you’re 15 times more likely to get Alzheimer’s if you have two copies of APOE4. But that’s not what the odds ratio actually tells you about your personal risk.

[12:08 –> 12:41] Dr. Ravi Kumar: It is a specific statistical tool, and it is not meant to be read the way it usually gets read online. The number that actually tells you something useful is your lifetime risk. Meaning, out of everyone with a given phenotype, what percentage actually go on to develop Alzheimer’s by a certain age? So a study in molecular psychiatry in 2011 put real numbers behind this. By age 85, a man with two APOE4 copies has roughly a 51% lifetime risk of Alzheimer’s, and a woman with two copies, roughly 60%.

[12:42 –> 13:23] Dr. Ravi Kumar: With one copy, it was roughly 23% for men and 30% for women. And in the general population, regardless of which APOE version you carry, lifetime risk of dementia by 85 years old sits around 11% for men and 14% for women. Now think about those numbers, because this is the part I actually really want you to remember. Even with two copies of the highest risk version of this gene, APOE4, roughly four in ten men and four in ten women reach 85 years old without ever developing Alzheimer’s disease. Two copies raises your risk substantially, but it does not decide your outcome, and that’s the thing to sit with.

[13:23 –> 13:54] Dr. Ravi Kumar: So here’s where we are. APOE is meant to move fat around your brain, and APOE4 is a slightly folded up version of that protein that’s less efficient at several of its jobs, jobs that, when they go wrong for long enough, help drive the disease process of Alzheimer’s. About a quarter of people in the world carry APOE4. It raises your risk substantially, but it does not determine your fate. And even people with the highest genetic risk can reach old age with their minds intact.

[13:55 –> 14:21] Dr. Ravi Kumar: Okay, so now that you understand the probabilities associated with APOE4, and hopefully you understand that it’s not a determination of your fate, let’s get back to the question that started this whole episode. If this gene is so horrible, why is it still here? Why wasn’t it weeded out of the gene pool a long time ago? Well, here’s the fact that puts it all into perspective. APOE4 is not the mutant.

[14:21 –> 15:10] Dr. Ravi Kumar: APOE4 is actually the original version of this protein. Gene sequencing work has compared the human APOE gene to the chimpanzee version, and the chimp gene most closely resembles the human APOE4 form. APOE3 and APOE2 are the newest versions, and that same research suggests that APOE3 has been steadily gaining ground on APOE4 over roughly the past 200,000 years, which is basically what natural selection looks like in slow motion. Something about APOE3 became more advantageous relatively recently in history, and that’s why the change is happening. Which means the real question isn’t why APOE4 is bad, it’s what APOE4 was good for and what changed.

[15:10 –> 15:51] Dr. Ravi Kumar: And the best evidence comes from studying people who still live closer to the ancestral condition of the human being. And the richest source of that data is actually the Tsimane, which are our forager horticulturalist population in the Bolivian Amazon who have been studied intensively for years. A study in 2017 looked at 372 Tsimane, ages six to 88, and tested cognition against parasite burden. Among Tsimane without signs of heavy parasite load, APOE4 carriers actually performed worse, recalling about 16% fewer words on short term memory tasks. It’s the same direction we see in the industrialized population.

[15:52 –> 16:17] Dr. Ravi Kumar: But among Tsimane carrying a heavy parasite burden, that flipped. APOE4 carriers held their cognitive performance, while non carriers declined in their cognition when they had heavy parasite loads. So APOE4 wasn’t a blanket advantage. It was an advantage under one specific condition, chronic infection. In a clean environment, having APOE4 cost you.

[16:17 –> 16:47] Dr. Ravi Kumar: In a world full of parasites, it actually protected you. Another study in 2021 looked at over 1,200 Tsimane adults, and found that APOE4 carriers ran roughly 30% lower C reactive protein levels, which is a common marker of systemic inflammation. So they had lower resting inflammation, and in a population constantly fighting infection. And that tells us something very specific about how APOE4 modulates the immune system. And I think it’s worth understanding.

[16:47 –> 17:12] Dr. Ravi Kumar: APOE4 carriers here don’t run hotter all the time. If anything, their baselines run a little bit cooler. But what’s different is how hard the immune system swings into action once a real threat shows up. Think of it less like a thermostat stuck on high and more like a smoke detector that’s super sensitive. It’s quiet when there’s no fire, and it’s the first to go off when there’s just a whiff of smoke.

[17:12 –> 18:06] Dr. Ravi Kumar: So in a world of internal parasites and constant low grade infection, that’s a great trait to have, honestly, because it’s efficient at rest and protective and activated against something that could otherwise kill you, like parasitic infections. And there’s also other evidence pointing in the exact same direction. Brazilian shantytown children who are living in unclean conditions and under long term surveillance found that among kids with heavy early childhood diarrheal illness, the ones carrying APOE4 did much better cognitively. So APOE4 in the ancestral environment is protective against infectious processes. And then there’s another finding with APOE4 that I think was a big advantage, and I think it’s actually the strongest of the whole set for explaining why APOE4 gene has persisted, and it has nothing to do with cognition.

[18:06 –> 18:56] Dr. Ravi Kumar: A study published in 2023 looked at 795 Tsimane women, ages 13 to 90, and women with one APOE4 allele had roughly 0.3 to 0.5 more children than women with no APOE4 allele. And women with two APOE4 alleles had somewhere between 1.4 and 2.1 more children. They started reproducing about 0.8 years earlier and had shorter gaps between births. And that study’s been partially replicated in a whole another setting. In a study in PLoS ONE in 2017, looking at over 4,000 women in rural Ghana, split by pathogen exposure based on their water source, Among older women in the high pathogen group, each APOE4 allele meant roughly one additional child.

[18:56 –> 19:27] Dr. Ravi Kumar: Two alleles meant about three and a half more children, and in the low exposure group, APOE4 did nothing. Imagine what an evolutionary advantage that is. Natural selection doesn’t care whether you’re healthy and quick witted at 75. Natural selection is a numbers game scored on how many descendants you leave behind. A gene that gives you two extra surviving children spreads through a population very fast, even if the price of having that gene doesn’t come due until 50 years later.

[19:27 –> 20:03] Dr. Ravi Kumar: So putting all this together, APOE4 is the ancestral human version of this gene associated with better fertility and better cognitive resilience under heavy pathogen load. It runs a quieter baseline immune system with a quicker and more effective immunological response pathogens. The payoffs for this show up early in life when reproductive success matters the most. So the genetic deal that our ancestors got looks something like this. APOE4 helped you survive childhood infection and helped you have more children in a hard, pathogen rich world.

[20:04 –> 20:23] Dr. Ravi Kumar: In exchange, it sent you a bill decades later, and it was a bill that almost nobody lived long enough to actually receive and pay. Now, what happened to that deal as we transitioned into the modern world? Well, three things changed. Let’s take them one at a time. The first is time.

[20:23 –> 20:44] Dr. Ravi Kumar: We live longer now. You’ll hear people say that our ancestors died at 30, so Alzheimer’s never had a chance to show up. And honestly, that’s a misreading of the data. Life expectancy at birth in hunter gatherer populations was around 32 years old, so that is true. But that number is dragged way down by infant and child mortality.

[20:44 –> 21:12] Dr. Ravi Kumar: It doesn’t describe an adult who actually made it past childhood. There’s a cross cultural analysis that pulled together mortality data across forging societies, And the picture is very different. If you survived to 15, you had a good shot of reaching your fifties. If you made it to 45, you could expect roughly another twenty years. The single most common age of death among adults in these societies is about 72 years old, not 30.

[21:12 –> 21:49] Dr. Ravi Kumar: Our ancestors who made it through childhood often grew old. But here’s the nuance that carries this whole argument forward. In 2002, there was a study of the Hadza, which is a hunter gatherer population, and they showed that for every 100 births, about 22 people reached the age of 70, about 25 reached the age of 65, and only 8 people reached 80. Now compare that to now, where the overwhelming majority of us reach 65, and a very large share of people reach 85 years old. That’s exactly where Alzheimer’s prevalence goes vertical.

[21:50 –> 22:22] Dr. Ravi Kumar: So the accurate version of this whole argument is not that nobody lived long in these hunter gatherer populations. Some actually did. The argument here, or the explanation here, is that far fewer person years were ever lived in the late window of life, So natural selection had very little leverage there. A gene that hurts you at 80 is nearly invisible to selection when only eight out of 100 people ever arrived at 80 years old. And of those people at 80 years old, they’re no longer reproductively active, most likely.

[22:23 –> 22:43] Dr. Ravi Kumar: The pressure to weed it out was almost nonexistent at this point, while the pressure to keep it through fertility and infection defense operated at full strength on everyone all the time. That asymmetry is the engine of the whole paradox. Okay. So the second thing that’s changed is our immune environment. And I think this is one of the most important.

[22:43 –> 23:29] Dr. Ravi Kumar: Remember how quickly APOE4 activated your immune system? Well, in a world of intestinal parasites, endemic infections, and no antibiotics, APOE4 had plenty of real fires to find and stay productively occupied. Now put that same sensitive detector in our modern bodies where most of us don’t carry chronic parasitic loads. What we carry instead is visceral fat, metabolically active tissue pumping out inflammatory signals around the clock, insulin resistance, disrupted sleep, an out of balance gut microbiome, and constant chronic stress. The detector doesn’t get less sensitive, it’s still sensitive, but it thinks there’s fires going on all the time.

[23:29 –> 24:06] Dr. Ravi Kumar: It just runs out and tries to put them out all the time over and over in… Over decades of life, and this leads to chronic inflammation. And in the brain, we call that neuroinflammation, which is the basis for Alzheimer’s disease. Okay, so I hope that’s pretty clear. APOE4 is fantastic at pulling the fire alarm and getting things going from an inflammatory standpoint, But when you’re constantly inflamed through all these modern lifestyle signals, that can basically cause APOE4 to run constantly, leading to systemic and brain inflammation.

[24:07 –> 24:29] Dr. Ravi Kumar: Okay. So the third thing that changed, and I think this is very important, is our food. Ultra processed food now makes up nearly 58% of the calories the average American eats in a day. It supplies almost 90% of the added sugar we consume. There’s a real change historically for most of human history and for essentially all of time that this gene has existed.

[24:29 –> 24:59] Dr. Ravi Kumar: Nobody was eating like this. And here’s why that matters. Eat that way constantly, and your blood sugar and your insulin spend a lot more time elevated than your body ever knew or evolved to handle. This is what I talk about all the time in this show, and it’s called metabolic syndrome. You become fat and inflamed from the constant deluge of glucose, which eventually leads to prediabetes and diabetes, and all these chronic diseases associated with chronically elevated glucose and insulin.

[25:00 –> 25:38] Dr. Ravi Kumar: And the connection between metabolic disease and dementia has been very well clinically established. A pooled analysis of over 2,000,000 people found that type 2 diabetes carries roughly 60% higher risk of dementia. So I think it’s pretty clear that metabolic disease and Alzheimer’s disease are heavily connected, and now we’re in this world where our food is driving us into metabolic syndrome, and it’s wrecking our brains. Okay. So the next question is, now that we know what’s changed and how this has led to APOE4 becoming a liability rather than an asset, is this.

[25:39 –> 26:09] Dr. Ravi Kumar: Is there anything that we can do that reduces our risk of dementia, even in the setting of APOE4? Well, luckily, there is a lot we can do. I like to call these interventions levers because you’re essentially pulling a lever that changes the physiological machinery in your body leading to a different outcome biologically. I think it’s a great metaphor, and I use it all the time in my podcast, so I’m gonna go with it on this one too. Lever one is sleep, and there’s real good human evidence on this.

[26:10 –> 26:59] Dr. Ravi Kumar: A study in 2018 kept 20 healthy adults awake for one full night, and scanned their brains before and after. Amyloid, that sticky protein that we talked about earlier that’s not well cleared in APOE4 carriers, rose by about 5% in the thalamus and hippocampus after just a single night of sleep deprivation. Separately, a study in JAMA Neurology in 2013 and nearly 700 older adults found better sleep consolidation substantially blunted the effect of the APOE4 allele on Alzheimer’s risk and on neurofibrillary tangled density at autopsy. Remember, the neurofibrillary tangles are those tangles of tau proteins that actually kill the neurons. There’s a proposed mechanism behind all of this, and it’s called the glymphatic system, which I love talking about.

[26:59 –> 27:33] Dr. Ravi Kumar: When you go to sleep at night, your brain pulses cerebrospinal fluid through your brain tissue, and it flushes out the toxins, the waste molecules, and the beta amyloid particles that often accumulate in APOE4 genotypes. So if you carry APOE4, sleep, and especially deep, slow wave sleep, isn’t a nice to have. It should be treated like the best medication you can take. I’ve done a whole podcast on optimizing your sleep, and if you haven’t listened to it, just go back through my library and take a listen. You’ll be really glad you did.

[27:34 –> 28:03] Dr. Ravi Kumar: Okay, so lever two is metabolic health, specifically insulin sensitivity. The single clearest gene environment interaction in the literature is diabetes. A 2002 study found that type 2 diabetes plus an APOE4 carrier carried a relative risk increase of 5.5x compared to having neither. So protecting your insulin sensitivity isn’t a general wellness goal here. It’s one of the most important levers you can pull.

[28:03 –> 28:30] Dr. Ravi Kumar: The third lever to pull is midlife cardiovascular health. Controlling your blood pressure is probably one of the most important things you can do in this realm. A 2001 BMJ study followed nearly 1,500 people for decades and found that high blood pressure in your 40s and 50s roughly doubled later Alzheimer’s risks. That holds up consistently, so keep it controlled in midlife, full stop. Now, as far as your cholesterol goes, that’s much messier.

[28:30 –> 29:23] Dr. Ravi Kumar: The same study found that high midlife cholesterol also doubled risk, and both together more than tripled it. But how cholesterol relates to brain health depends a lot on when in life you’re looking at the cholesterol levels and what else is going on metabolically, which is a longer conversation, and I’ve gone very deep on this in past episodes. But for now, just get your numbers checked with your doctor, and don’t panic over one cholesterol number in isolation, especially later in life. Separately, a 2005 BMJ study following over 10,000 people for 27 years found midlife obesity, which is part of metabolic health, by itself was associated with a 74% higher risk of later dementia. So get your metabolic health, and your weight, and your muscle mass, and all the things that lead to a metabolically healthy diet, which I’ve talked a lot about on this show, get that all locked in.

[29:24 –> 29:40] Dr. Ravi Kumar: Okay. So lever four is structured movement and mental engagement. Aerobic exercise several days a week, resistance training, a Mediterranean style diet, and cognitive and social engagement. These are all super powerful lifestyle changes. There’s not one heroic intervention here.

[29:41 –> 30:04] Dr. Ravi Kumar: It’s actually a bundle of lifestyle factors that lead to overall better health and resilience. I’ve talked a lot about these on my show. You can go back, search Mediterranean diet, search resistance training, look up sleep, look up metabolic health. It’s all there, and it’s all just waiting for you to implement it. It’s free, and it will make you a better person and give you a lower chance of Alzheimer’s disease later in life.

[30:05 –> 30:40] Dr. Ravi Kumar: Okay. So those are the four main levers I tell everyone to pull. But there are other significant things that you can do to reduce your dementia risk, whether you have APOE4 or not. The Lancet commissioned a report in 2024 that listed 14 modifiable risk factors across a lifetime, estimating up to 45% of dementia cases worldwide could theoretically be prevented if every one of these were fully eliminated. That’s a population statistic, and it tells you what happens across millions of people, not what happens to you personally if you actually have one of these risk factors.

[30:40 –> 30:58] Dr. Ravi Kumar: So let me give you some numbers that are actually useful. I’ll tell you how much higher your risk runs if you have one of these risk factors. And the reason I’m telling you this is because each one of these may be potentially fixable, which reduces your dementia risk later on in life. Okay. So let’s start with hearing loss.

[30:58 –> 31:34] Dr. Ravi Kumar: The commission’s own pool data puts it at roughly a thirty to 90% higher individual risk of dementia if you have uncorrected hearing loss. But if you combine the estimates, it comes out at approximately 37% higher of dementia if you do not correct hearing loss. And here’s the part I find really exciting, because most of what I’ve told you today is correlation with caveats attached to it. In this one, it’s different. A randomized trial called ACHIEVE, published in The Lancet in 2023, gave older adults either hearing aids or a health education program and followed them for three years.

[31:35 –> 31:56] Dr. Ravi Kumar: In the group already at higher baseline risk, hearing aids cut the rate of cognitive decline by roughly half. That’s not association anymore. That’s a controlled trial showing a fix that actually works. So if you have hearing loss, see your doctor and get hearing aids. It could make a massive difference in your brain health.

[31:56 –> 32:31] Dr. Ravi Kumar: Okay, so the next risk factor is social isolation. Social isolation and loneliness track with roughly 55% to 60% higher individual risk of dementia based on a 2015 meta analysis of over 15,000 people. We don’t normally think of social isolation as a disease state, but it really is. It affects your brain, it affects your cardiovascular system, it affects your overall health, and affects your happiness. And often, people who are depressed or their health is failing become more socially isolated, which feeds into a vicious cycle.

[32:32 –> 32:51] Dr. Ravi Kumar: So if you or your loved one is isolated, find ways to get out and talk to people. You need to interact. It’s some of the best medicine you can take. Untreated vision loss is the newest identified risk factor for dementia. Dementia runs about 38% higher in people who have uncorrected vision loss.

[32:51 –> 33:30] Dr. Ravi Kumar: We don’t have a clinical trial here like we had with the hearing loss study, but a large study on cataract surgery specifically found that it was associated with a meaningful lower risk of Alzheimer’s disease afterwards, meaning they fixed people’s cataracts, helped them see better, and they had lower risk of Alzheimer’s afterwards. The next risk factor, and one that’s very clear, is smoking. Current smokers run about a 30% higher risk of dementia than people who have never smoked, and people who quit don’t carry the same elevated risk that smokers do. I know I say this all the time, but smoking does nothing but tear you down. If you smoke, just stop.

[33:30 –> 33:49] Dr. Ravi Kumar: Ask your doctor for help. There are great drugs like varenicline that can make quitting completely possible if you previously thought that it just wasn’t. Okay. So the next risk factor is depression, And depression is a massive risk factor for dementia. It doubles your risk and needs to be addressed no matter what stage of life you’re in.

[33:50 –> 34:15] Dr. Ravi Kumar: Depression can actually damage the brain over years, and it can also be an early symptom of dementia before any diagnosis shows up. That’s exactly why treating it can be very high yield. I’ve done a two part podcast on understanding and treating depression. If you or someone you love is suffering with depression, please listen to that series. Go back through my history, find it, and listen to the part one and part two.

[34:15 –> 34:37] Dr. Ravi Kumar: It’ll help you understand depression and help… And give you hope that you can get over it because it is fixable and curable. You can also download a roadmap off my website, which is linked to in that podcast. Okay, so alcohol is the next risk factor, and it’s more nuanced than the other ones. First, I wanna say that alcohol is by definition a neurotoxin.

[34:37 –> 35:07] Dr. Ravi Kumar: There are no redeeming chemical qualities to alcohol in your body. Hard stop. But light to moderate drinking has not shown clear excess risk for dementia. Heavier midlife drinking, more than about two drinks a day, tracks with somewhere around 20% higher risk of dementia. And diagnosed alcohol use disorder, the clinical far end of the spectrum of alcoholism, was linked to more than triple the risk in a French National Registry study, covering over 30 million people.

[35:07 –> 35:29] Dr. Ravi Kumar: So it’s safe to say that heavy alcohol use is a great way to wreck your brain. Ask your doctor for help if you plan to quit, as alcohol withdrawals can be dangerous. Okay, so the last risk factor I want to talk about is air pollution. And this is not one that most of you would think about, but it’s a real risk for dementia. And it works on a sliding scale rather than an on and off switch.

[35:30 –> 35:55] Dr. Ravi Kumar: Each increase in fine particulate exposure nudges your risk of dementia up a little each time, and it adds up over a lifetime. So if you are exposed to chronic air pollution and you have a way to modify it with indoor air filtration or just moving to a cleaner environment, this is well worth the change when it comes to your dementia risk and your overall health. Okay. So that was a lot. Let me sum it up for you.

[35:55 –> 36:25] Dr. Ravi Kumar: And here’s what I want you to walk away with. APOE4 is not a defect. It’s a well designed piece of biology tuned for a world of infection, scarcity, and early reproduction, and it now runs inside bodies like mine living in a world of abundance, sterility, and 80 year lifespans. The gene didn’t change, but the environment did. And that reframe matters, because a defect is something you have and can’t really do anything about.

[36:26 –> 36:52] Dr. Ravi Kumar: A mismatch is something that if you understand, you can actually modify your environment to better fit that mismatch. Okay, so there was a fact that I mentioned early in the podcast that I asked you to hold onto, and it was this. Nearly every person with two copies of APOE4 develops the Alzheimer’s pathology in their brains. Remember, that’s the amyloid and the tau with the neurofibrillary tangles. You see it under the microscope, you can see it on scans.

[36:52 –> 37:22] Dr. Ravi Kumar: But about half of them still reach the age of 85 years old without any dementia. Their minds are clear and strong. Something is protecting these people. Some of it’s lifestyle, and some of it’s other genes that we just don’t fully understand yet. But much of what prevents dementia in those otherwise high risk people, like me, are lifestyle factors that we just talked through, and none of that requires a prescription, except for maybe the hearing aids and the glasses.

[37:23 –> 37:55] Dr. Ravi Kumar: So if you’ve been carrying around an APOE4 result like a diagnosis, I hope this episode loosened its grip on you a little. It’s a risk factor, but it’s not a verdict or a destiny. And it also tells you something useful, which is exactly where you can aim your lifestyle interventions. I myself am an APOE4/E3 heterozygote, and I’m not scared of dementia. I’m doing the things now and into the future that will keep me metabolically healthy and resilient for a lifetime of healthy cognition.

[37:56 –> 38:18] Dr. Ravi Kumar: So if you take just one thing from this episode, it should be this. The most powerful tools we have against this disease are still sleep, movement, food, and metabolic health. That’s not a disappointing answer, folks. That’s an empowering one, because every single one of those is fully modifiable by you. Okay, folks.

[38:18 –> 38:19] Dr. Ravi Kumar: Cheers. I’ll see you next week.

Get Dr. Kumar's free health protocols

Evidence-based playbooks from Dr. Ravi Kumar, MD, a board-certified neurosurgeon, plus a weekly research review. Enter your email and I'll send you the relevant protocol.

By subscribing, you agree to receive emails from The Dr Kumar Discovery. You can unsubscribe at any time. Privacy Policy